The Psychopharmacologic Drugs Advisory Committee (PDAC) was not playing the tune Alexza Pharmaceuticals Inc. wanted to hear Monday as the committee tried to harmonize safety concerns for Adasuve with its benefits in treating acute agitation in patients with schizophrenia or bipolar disorder.